1. Home
  2. CBIO vs ILPT Comparison

CBIO vs ILPT Comparison

Compare CBIO & ILPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$11.74

Market Cap

389.7M

Sector

N/A

ML Signal

N/A

Logo Industrial Logistics Properties Trust of Beneficial Interest

ILPT

Industrial Logistics Properties Trust of Beneficial Interest

N/A

Current Price

$6.08

Market Cap

408.6M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
CBIO
ILPT
Founded
2003
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
389.7M
408.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
CBIO
ILPT
Price
$11.74
$6.08
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$26.67
N/A
AVG Volume (30 Days)
163.9K
226.3K
Earning Date
01-01-0001
05-19-2026
Dividend Yield
N/A
3.21%
EPS Growth
N/A
31.51
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$3.05
Revenue Next Year
N/A
$2.21
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.72
$2.45
52 Week High
$17.39
$6.68

Technical Indicators

Market Signals
Indicator
CBIO
ILPT
Relative Strength Index (RSI) 52.76 53.69
Support Level $10.45 $5.10
Resistance Level $13.37 $6.57
Average True Range (ATR) 0.91 0.24
MACD 0.07 0.00
Stochastic Oscillator 38.00 35.99

Price Performance

Historical Comparison
CBIO
ILPT

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About ILPT Industrial Logistics Properties Trust of Beneficial Interest

Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.

Share on Social Networks: